:format(webp)/cdn.mskdoctors.com/storage/2026/8/m5hussZZ9owL5cSOW8JGtSBbGitjmL5I.jpg)
ChondroFiller repeat injections and long-term repairChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.ChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/0TUtcyt4GXbxiF6gJem8IBQTJxdBjdy1.jpg)
When cartilage repair is the right choiceCartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/WyTUgPyuRTUUHCpsWkxQLHIH1zV03yj2.jpg)
Can ChondroFiller delay joint replacement?An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/K0tLM5AwmOmwkPaB2Har1ULtTxYwLkJY.jpg)
ChondroFiller vs Liquid Cartilage for focal cartilage defectsAn injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.An injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/xTIhoJvVdRDxE765Je6PwQ1abvBdgJEl.jpg)
ChondroFiller injection cost in the UKChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.ChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/iVkAeySfTXIy2JOZ11BErGf2bexg8dSF.jpg)
ChondroFiller injection for knee cartilage defectsThe injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.The injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.
:format(webp)/cdn.mskdoctors.com/storage/2026/8/fI1OLTY4rXZmoPULfTGjujCUV9qyYume.jpg)
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/8c3WGhTDSa50H5g1A54m11iCswgvY7B4.jpg)
Single-stage vs two-stage ACI for cartilage repairTraditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/qK5QIjTamPhwMv8E9NkiBLXaSBf3Bofl.jpg)
ChondroFiller for focal knee defects versus early osteoarthritisFocal cartilage defects and early osteoarthritis produce identical symptoms but differ structurally — a contained lesion versus compartment-wide degeneration — and imaging determines which pathway applies. ChondroFiller, an injectable collagen scaffold into which the body's progenitor cells migrate and lay down new cartilage tissue, addresses only focal lesions.Focal cartilage defects and early osteoarthritis produce identical symptoms but differ structurally — a contained lesion versus compartment-wide degeneration — and imaging determines which pathway applies. ChondroFiller, an injectable collagen scaffold into which the body's progenitor cells migrate and lay down new cartilage tissue, addresses only focal lesions.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/S6fB5FURIu0CvCfaH3a2BsSKF1F6KZtW.jpg)
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/dvccGEXe5bvyiNTHH0hLtDi8GkVGoaWM.jpg)
Recovery after a ChondroFiller injectionChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.ChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/zKztwrt8KaoDb73OWJr53Zg4tZADHBlu.jpg)
What ChondroFiller's CE approval means for UK patientsChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
